BJ
JUNO

BlackRock Japan’s Juno Therapeutics, Inc. JUNO Stock Holding History

BlackRock Japan’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-311
Closed -$17K – 1422
2015
Q2 		$17K Buy
+311
New +$16.5K ﹤0.01% 1221

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM

BlackRock Japan's JUNO Position: Q3 2015 in Review

BlackRock Japan sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2015, closing a stake of 311 shares — an estimated $17K sold.

BlackRock Japan first reported a position in JUNO in Q2 2015 and held it in 1 quarter. The position peaked at $17K in Q2 2015. 132 funds tracked by Wall St. Rank hold JUNO as of Q3 2015.

  • BlackRock Japan reported no remaining Juno Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • BlackRock Japan sold 311 Juno Therapeutics, Inc. shares in Q3 2015, an estimated $17K.
  • BlackRock Japan first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • BlackRock Japan's Juno Therapeutics, Inc. position peaked at $17K in Q2 2015.
  • 132 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2015.

Based on BlackRock Japan's 13F filing for Q3 2015, filed 13 Nov 2015.